Hyperlipidemia results in endothelial dysfunction, which is intimately associated with disturbed mitochondrial homeostasis, and is a real risk factor for cardiovascular diseases (CVDs). Triphenylphosphonium (TPP+)-HT, constructed by linking a mitochondrial-targeting moiety TPP+ to hydroxytyrosol (HT), enters the cell and accumulates in mitochondria and is thus an important candidate drug for preventing hyperlipidemia-induced endothelial injury. In the present study, we found that TPP-HT has a better anti-inflammatory effect than HT. In vivo, TPP-HT significantly prevented hyperlipidemia-induced adverse changes in the serological lipid panel, as well as endothelial and mitochondrial dysfunction of the thoracic aorta. Similarly, in vitro, TPP-HT exhibited similar protective effects in palmitate (PA)-induced endothelial dysfunction, particularly enhanced expression of the mitochondrial ETC complex II, recovered FoxO1 expression in PA-injured human aorta endothelial cells (HAECs) and promoted FoxO1 nuclear translocation. We further demonstrated that FoxO1 plays a pivotal role in regulating ATP production in the presence of TPP-HT by using the siFoxO1 knockdown technique. Simultaneously, TPP-HT enhanced Nrf2 nuclear translocation, consistent with the in vivo findings of immunofluorescence, and the antioxidant effect of TPP-HT was almost entirely blocked by siNrf2. Concomitantly, TPP-HT’s anti-inflammatory effects in the current study were primarily mediated via the p38 MAPK/NF-κB signaling pathway in addition to the FoxO1 and Nrf2 pathways. In brief, our findings suggest that mitochondria-targeted TPP-HT prevents lipotoxicity induced endothelial dysfunction by enhancing mitochondrial function and redox balance by promoting FoxO1 and Nrf2 nuclear translocation.
As the most important natural antioxidants in plant extracts, polyphenols demonstrate versatile bioactivities and are susceptible to oxidation. The commonly used ultrasonic extraction often causes oxidation reactions involving the formation of free radicals. To minimize the oxidation effects during the ultrasonic extraction process, we designed a hydrogen (H2)-protected ultrasonic extraction method and used it in Chrysanthemum morifolium extraction. Hydrogen-protected extraction improved the total antioxidant capacity, 2,2-diphenyl-1-picrylhydrazyl (DPPH) radical scavenging activity, and polyphenol content of Chrysanthemum morifolium water extract (CME) compared with air and nitrogen (N2) conditions. We further investigated the protective effects and mechanisms of CME on palmitate (PA)-induced endothelial dysfunction in human aorta endothelial cells (HAECs). We found that hydrogen-protected CME (H2-CME) best-prevented impairment in nitric oxide (NO) production, endothelial NO synthase (eNOS) protein level, oxidative stress, and mitochondrial dysfunction. In addition, H2-CME prevented PA-induced endothelial dysfunction by restoring mitofusin-2 (MFN2) levels and maintaining redox balance.
Cardiovascular diseases remain the leading cause of global mortality, with endothelial dysfunction recognized as a critical initiating event. Hyperlipidemia-induced endothelial lipotoxicity triggers oxidative stress and inflammation, thereby accelerating vascular injury. Given the central role of endothelial cells in maintaining vascular homeostasis, they represent a key therapeutic target for mitigating systemic lipotoxicity. However, specific strategies aimed at countering endothelial lipotoxicity remain limited, highlighting an urgent need for novel pharmacological interventions. 6-Gingerol, a primary bioactive constituent of ginger (Zingiber officinale) and related plants, exhibits potent antioxidant, anti-inflammatory, and anticancer properties. Nevertheless, its potential protective effects against hyperlipidemia-induced endothelial injury and the underlying mechanisms remain incompletely understood. In this study, we investigated the protective effects of 6-gingerol and explored its mechanisms of action using both in vivo and in vitro models of endothelial dysfunction. Our results demonstrated that 6-gingerol effectively ameliorates inflammation and oxidative stress associated with endothelial dysfunction induced by hyperlipidemia. Mechanistically, under Nrf2 knockdown conditions, the antioxidant effects of 6-gingerol were abolished. Similarly, inhibition of Erk with U0126 blocked 6-gingerol-mediated nuclear translocation of Nrf2 and its antioxidant activity, underscoring the critical role of the Erk–Nrf2 axis in mediating these effects. Moreover, transcriptomic analysis and pharmacological interventions using a p38 MAPK inhibitor and an NF-κB inhibitor revealed that 6-gingerol suppresses the release of inflammatory mediators, such as IL-6, via the p38 MAPK–NF-κB signaling pathway. In summary, our study provides evidence that 6-gingerol ameliorates lipotoxicity-induced endothelial injury through coordinated modulation of the Erk–Nrf2 and p38–NF-κB signaling pathways, highlighting its potential as a novel preventive candidate for endothelial dysfunction in cardiovascular diseases.
1 April 2025 in Drug Design, Development and Therapy
Background and Objective: Hydroxytyrosol (HT) is reported to protect endothelial cells against metabolic overload through inhibiting inflammation. However, the hydrophilic nature of HT limits its oral bioavailability and biological efficiency. The aim of the study was to design and synthesize novel hybrid molecules to improve HT’s biological efficiency. Materials and Methods: A pharmacophore connection strategy was used to design and synthesize novel hybrid molecules by combining HT or its analogues with adamantane (ADM). Palmitic acid (PA) was used to induce lipid overload in HAEC cells, and P407 was used to induce acute hyperlipidemia in C57 mice. Results: We found that DP-ADM, combining ADM and dopamine (a HT analogues), exhibited potent protective effects against metabolic overload-induced endothelial dysfunction. DP-ADM showed low toxicity and inhibited inflammation in response to PA overload in cultured endothelial cells. Additionally, it (30 mg/kg) decreased circulating lipids to an extent similar to HT in a mouse model of hyperlipidemia and was superior to HT in decreasing circulating inflammatory cytokine. It was also superior to HT in improving vascular endothelial function in mice with hyperlipidemia. Mechanistically, DP-ADM inactivated MAPK signaling, as evidenced by downregulated phosphorylation of p38 and Erk. Inhibition of MAPK or NF-κB abolished the anti-inflammatory effect of DP-ADM. Specifically, DP-ADM activated FoxO1 signaling and increased mitochondrial biogenesis in endothelial cells. Conclusion: Overall, DP-ADM is a superior form of HT, highlighting its potential therapeutic use in improving endothelial function in metabolic diseases.